Artificially Engineered SC Function Control System for Schwann Cell Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack a fundamental solution for diseases caused by Schwann cell dysfunction, such as Charcot-Marie-Tooth disease type 1A, relying on partial symptom relief through physical therapy and orthopedic aids.
Innovation Solution
An artificially manipulated Schwann cell (SC) function-controlling system, comprising a genetically modified SC function-controlling factor, is developed to artificially control SC functions and treat SC dysfunction-associated diseases. This system includes a guide nucleic acid-editor protein complex that modifies the PMP22 gene, allowing for precise manipulation of SC functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If physical therapy and orthopedic aids are used to treat Schwann cell dysfunction diseases, then symptom aggravation can be partially reduced, but no fundamental therapeutic solution is achieved
Solution Approach 1:
The patent replaces mechanical/physical therapy methods with a genetic manipulation system that directly addresses the root cause of Schwann cell dysfunction. The CRISPR-Cas9 based system modifies the PMP22 gene to restore normal Schwann cell function, eliminating the need for symptomatic physical therapies and orthopedic aids.
Solution Approach 2:
The genetically manipulated Schwann cells are designed to self-correct the dysfunction by restoring normal PMP22 gene expression. The system enables the cells to autonomously regulate their own function through modified gene expression, eliminating the need for continuous external physical therapy intervention.
2Reliability
If genetic manipulation of PMP22 gene is performed to control Schwann cell function, then fundamental therapeutic solution is achieved, but the system complexity increases
Solution Approach 1:
The patent employs the CRISPR-Cas9 system, a universal genetic manipulation platform that can target multiple genes and applications. This multi-functional system allows the same Cas9 protein and guide RNA mechanism to be used for PMP22 gene modification, demonstrating broad applicability beyond this specific disease treatment.
Solution Approach 2:
The patent uses guide RNA as an intermediary molecule that directs the Cas9 protein to the specific PMP22 gene target sequence. This intermediary enables precise gene targeting without requiring complex protein-protein recognition systems, simplifying the overall manipulation approach.
3Reliability
If Schwann cell function is artificially controlled through genetic manipulation, then SC dysfunction diseases can be treated, but precision of gene targeting is challenged
Solution Approach 1:
The patent employs guide RNA with highly specific nucleotide sequences that are designed to match only the target PMP22 gene region. This local sequence complementarity ensures that the Cas9-gRNA complex binds exclusively to the intended genomic location, achieving precise targeting without affecting other genes.
Solution Approach 2:
The system incorporates mechanisms to verify successful gene editing through detection of PMP22 expression changes. This feedback allows confirmation that the manipulation achieved the desired therapeutic effect while maintaining safety through monitoring of off-target effects.
Data Source
AI summary
The present invention relates to an artificially manipulated SC function-controlling factor for SC function control and/or the treatment or alleviation of a disease due to an SC function disorder, and to a use thereof. More specifically, the present invention relates to a system capable of performing artificial SC function control and/or treating or alleviating a disease due to an SC function disorder, the system comprising: an artificially manipulated SC function-controlling factor for SC function control and/or the treatment or alleviation of a disease due to an SC function disorder; and/or a composition for treating or alleviating a disease due to an SC function disorder. In a specific aspect, the present invention relates to an SC function-controlling system by an SC function-controlling factor, such as artificially manipulated PMP22, and/or an expression product thereof.